BREAKTHROUGH: All 18 hospitalized individuals at the Ziv Medical Center in Safed that were administered Amor-18 from Amorphical, recovered in a phase II trial and were shortly discharged.
All 18 COVID-19 patients hospitalized with moderate or severe symptoms who were administered the drug Amor-18 developed by Israeli biotech company Amorphical in a phase II clinical trial recovered and were discharged in a few days, the company announced Wednesday. Of the 19 individuals who were given a placebo, six had to be transferred to intensive care, and two died.
The trial was conducted at the Ziv Medical Center in Safed and led by the directors of the coronavirus department, Dr. Continue Reading »